Search

Your search keyword '"Qu, Wenjia"' showing total 143 results

Search Constraints

Start Over You searched for: Author "Qu, Wenjia" Remove constraint Author: "Qu, Wenjia"
143 results on '"Qu, Wenjia"'

Search Results

2. The potential of epigenetic therapy to target the 3D epigenome in endocrine-resistant breast cancer

5. Self-assembly of Dawson-type H6P2W18O62@[Cu6O(TZI)3(H2O)6]4 for high-performance aerobic oxidation desulfurization of fuel.

8. Quantitative comparison of DNA methylation assays for biomarker development and clinical applications

11. Epigenetic reprogramming at estrogen-receptor binding sites alters 3D chromatin landscape in endocrine-resistant breast cancer

13. Supplementary Figure 4 from Epigenetic Deregulation Across Chromosome 2q14.2 Differentiates Normal from Prostate Cancer and Provides a Regional Panel of Novel DNA Methylation Cancer Biomarkers

14. Supplementary Figure 1 from Epigenetic Deregulation Across Chromosome 2q14.2 Differentiates Normal from Prostate Cancer and Provides a Regional Panel of Novel DNA Methylation Cancer Biomarkers

15. Supplementary Tables 1-3 from Epigenetic Deregulation Across Chromosome 2q14.2 Differentiates Normal from Prostate Cancer and Provides a Regional Panel of Novel DNA Methylation Cancer Biomarkers

16. Data from Epigenetic Deregulation Across Chromosome 2q14.2 Differentiates Normal from Prostate Cancer and Provides a Regional Panel of Novel DNA Methylation Cancer Biomarkers

17. Supplementary Table and Figure Legends from Epigenetic Deregulation Across Chromosome 2q14.2 Differentiates Normal from Prostate Cancer and Provides a Regional Panel of Novel DNA Methylation Cancer Biomarkers

18. Supplementary Figure 3 from Epigenetic Deregulation Across Chromosome 2q14.2 Differentiates Normal from Prostate Cancer and Provides a Regional Panel of Novel DNA Methylation Cancer Biomarkers

19. Supplementary Figure 2 from Epigenetic Deregulation Across Chromosome 2q14.2 Differentiates Normal from Prostate Cancer and Provides a Regional Panel of Novel DNA Methylation Cancer Biomarkers

21. Methylome and transcriptome maps of human visceral and subcutaneous adipocytes reveal key epigenetic differences at developmental genes

23. Comprehensive methylome sequencing reveals prognostic epigenetic biomarkers for prostate cancer mortality

27. Interaction of Epididymal Epithelia and their Secretions with Spermatozoa Supports Functional and Morphological Changes During Long-Term Storage in the Chinese Soft-Shelled Turtle (Pelodiscus sinensis)

28. GUIDE: a randomised non-comparative phase II trial of biomarker-driven intermittent docetaxel versus standard-of-care docetaxel in metastatic castration-resistant prostate cancer (clinical trial protocol)

29. Interaction of Epididymal Epithelia and their Secretions with Spermatozoa Supports Functional and Morphological Changes During Long-Term Storage in the Chinese Soft-Shelled Turtle (

34. Serum Free Methylated Glutathione S-transferase 1 DNA Levels, Survival, and Response to Docetaxel in Metastatic, Castration-resistant Prostate Cancer: Post Hoc Analyses of Data from a Phase 3 Trial

35. DNA Hypermethylation Encroachment at CpG Island Borders in Cancer Is Predisposed by H3K4 Monomethylation Patterns

36. Evaluation of cross-platform and interlaboratory concordance via consensus modelling of genomic measurements

37. Enduring epigenetic landmarks define the cancer microenvironment

38. Replication timing shapes the cancer epigenome and the nature of chromosomal rearrangements

39. Acetylated histone variant H2A.Z is involved in the activation of neo-enhancers in prostate cancer

40. Post hoc analysis of a phase III study to test the association between circulating methylated glutathione s transferase (mGSTP1) DNA levels and response to docetaxel (DTX) in metastatic castration resistant prostate cancer (mCRPC).

41. Quantitative comparison of DNA methylation assays for biomarker development and clinical applications

42. Evaluation of cross-platform and interlaboratory concordance via consensus modelling of genomic measurements.

43. Quantitative comparison of DNA methylation assays for biomarker development and clinical applications

44. GUIDE: A randomized non-comparative phase II trial of biomarker-driven intermittent docetaxel versus standard-of-care docetaxel in metastatic castration-resistant prostate cancer (ANZUP 1903).

45. Methylome sequencing in triple-negative breast cancer reveals distinct methylation clusters with prognostic value

46. Circulating microRNAs associated with docetaxel-resistant castration resistant prostate cancer.

47. GWAS of DNA methylation variation within imprinting control regions suggests parent-of-origin association

48. Impact of the genome on the epigenome is manifested in DNA methylation patterns of imprinted regions in monozygotic and dizygotic twins

Catalog

Books, media, physical & digital resources